Viridian Therapeutic (VRDN) PT Raised to $34 at RBC Capital May 6, 2026 04:20AM
Viridian Therapeutic (VRDN) PT Lowered to $30 at RBC Capital Apr 7, 2026 05:44AM
RBC: 'we expect to see a negative impact to VRDN's shares', Shares 24% Today Apr 6, 2026 11:45AM
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns' Mar 18, 2026 09:21AM
Viridian Therapeutic (VRDN) PT Raised to $45 at RBC Capital Nov 6, 2025 04:26AM


Dec 17, 2024 09:16AM RBC on Viridian (VRDN): 'Compelling THRIVE-2 Data Could Change the Game for Chronic TED & VRDN'; PT Raised
Sep 13, 2024 06:33AM Viridian Therapeutic (VRDN) PT Raised to $44 at RBC Capital
Sep 12, 2024 06:12AM Viridian Therapeutics (VRDN) Prices Upsized 10.67M Share Offering at $18.75/sh
Sep 11, 2024 11:25PM Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
Sep 10, 2024 04:01PM Viridian Therapeutics (VRDN) Announces Proposed $150M Share and Warrant Offering
Sep 10, 2024 04:01PM Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
Jun 11, 2024 12:47PM RBC Capital Reiterates Outperform Rating on Viridian Therapeutic (VRDN)